Is the Market Bullish or Bearish on Krystal Biotech?
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
PMLive3d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings
Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...
A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts
The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price ...
Seeking Alpha6d
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Krystal Biotech (KRYS) and Treace Medical Concepts (TMCI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Krystal Biotech ...